Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years

Children With Hypoglycemia and Their Later Development (CHYLD) Study Team

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

IMPORTANCE: Hypoglycemia is common during neonatal transition and may cause permanent neurological impairment, but optimal intervention thresholds are unknown. OBJECTIVE: To test the hypothesis that neurodevelopment at 4.5 years is related to the severity and frequency of neonatal hypoglycemia. DESIGN, SETTING, AND PARTICIPANTS: The Children With Hypoglycemia and Their Later Development (CHYLD) Study is a prospective cohort investigation of moderate to late preterm and term infants born at risk of hypoglycemia. Clinicians were masked to neonatal interstitial glucose concentrations; outcome assessors were masked to neonatal glycemic status. The setting was a regional perinatal center in Hamilton, New Zealand. The study was conducted from December 2006 to November 2010. The dates of the follow-up were September 2011 to June 2015. Participants were 614 neonates born from 32 weeks’ gestation with at least 1 risk factor for hypoglycemia, including diabetic mother, preterm, small, large, or acute illness. Blood and masked interstitial glucose concentrations were measured for up to 7 days after birth. Infants with hypoglycemia (whole-blood glucose concentration <47 mg/dL) were treated to maintain blood glucose concentration of at least 47 mg/dL. EXPOSURES: Neonatal hypoglycemic episode, defined as at least 1 consecutive blood glucose concentration less than 47 mg/dL, a severe episode (<36 mg/dL), or recurrent (3 episodes). An interstitial episode was defined as an interstitial glucose concentration less than 47 mg/dL for at least 10 minutes. MAIN OUTCOMES AND MEASURES: Cognitive function, executive function, visual function, and motor function were assessed at 4.5 years. The primary outcome was neurosensory impairment, defined as poor performance in one or more domains. RESULTS: In total, 477 of 604 eligible children (79.0%) were assessed. Their mean (SD) age at the time of assessment was 4.5 (0.1) years, and 228 (47.8%) were female. Those exposed to neonatal hypoglycemia (280 [58.7%]) did not have increased risk of neurosensory impairment (risk difference [RD], 0.01; 95% CI, −0.07 to 0.10 and risk ratio [RR], 0.96; 95% CI, 0.77 to 1.21). However, hypoglycemia was associated with increased risk of low executive function (RD, 0.05; 95% CI, 0.01 to 0.10 and RR, 2.32; 95% CI, 1.17 to 4.59) and visual motor function (RD, 0.03; 95% CI, 0.01 to 0.06 and RR, 3.67; 95% CI, 1.15 to 11.69), with highest risk in children exposed to severe, recurrent, or clinically undetected (interstitial episodes only) hypoglycemia. CONCLUSIONS AND RELEVANCE: Neonatal hypoglycemia was not associated with increased risk of combined neurosensory impairment at 4.5 years but was associated with a dose-dependent increased risk of poor executive function and visual motor function, even if not detected clinically, and may thus influence later learning. Randomized trials are needed to determine optimal screening and intervention thresholds based on assessment of neurodevelopment at least to school age.

Original languageEnglish
Pages (from-to)972-983
Number of pages12
JournalJAMA Pediatrics
Volume171
Issue number10
DOIs
Publication statusPublished - 1 Oct 2017
Externally publishedYes

Fingerprint

Hypoglycemia
Executive Function
Blood Glucose
Odds Ratio
Glucose
New Zealand
Hypoglycemic Agents
Premature Infants
Cognition
Mothers
Learning
Parturition
Newborn Infant
Pregnancy

Cite this

Children With Hypoglycemia and Their Later Development (CHYLD) Study Team (2017). Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years. JAMA Pediatrics, 171(10), 972-983. https://doi.org/10.1001/jamapediatrics.2017.1579
Children With Hypoglycemia and Their Later Development (CHYLD) Study Team. / Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years. In: JAMA Pediatrics. 2017 ; Vol. 171, No. 10. pp. 972-983.
@article{12cefcfe4b484a73aee6a4fee36ebfc8,
title = "Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years",
abstract = "IMPORTANCE: Hypoglycemia is common during neonatal transition and may cause permanent neurological impairment, but optimal intervention thresholds are unknown. OBJECTIVE: To test the hypothesis that neurodevelopment at 4.5 years is related to the severity and frequency of neonatal hypoglycemia. DESIGN, SETTING, AND PARTICIPANTS: The Children With Hypoglycemia and Their Later Development (CHYLD) Study is a prospective cohort investigation of moderate to late preterm and term infants born at risk of hypoglycemia. Clinicians were masked to neonatal interstitial glucose concentrations; outcome assessors were masked to neonatal glycemic status. The setting was a regional perinatal center in Hamilton, New Zealand. The study was conducted from December 2006 to November 2010. The dates of the follow-up were September 2011 to June 2015. Participants were 614 neonates born from 32 weeks’ gestation with at least 1 risk factor for hypoglycemia, including diabetic mother, preterm, small, large, or acute illness. Blood and masked interstitial glucose concentrations were measured for up to 7 days after birth. Infants with hypoglycemia (whole-blood glucose concentration <47 mg/dL) were treated to maintain blood glucose concentration of at least 47 mg/dL. EXPOSURES: Neonatal hypoglycemic episode, defined as at least 1 consecutive blood glucose concentration less than 47 mg/dL, a severe episode (<36 mg/dL), or recurrent (3 episodes). An interstitial episode was defined as an interstitial glucose concentration less than 47 mg/dL for at least 10 minutes. MAIN OUTCOMES AND MEASURES: Cognitive function, executive function, visual function, and motor function were assessed at 4.5 years. The primary outcome was neurosensory impairment, defined as poor performance in one or more domains. RESULTS: In total, 477 of 604 eligible children (79.0{\%}) were assessed. Their mean (SD) age at the time of assessment was 4.5 (0.1) years, and 228 (47.8{\%}) were female. Those exposed to neonatal hypoglycemia (280 [58.7{\%}]) did not have increased risk of neurosensory impairment (risk difference [RD], 0.01; 95{\%} CI, −0.07 to 0.10 and risk ratio [RR], 0.96; 95{\%} CI, 0.77 to 1.21). However, hypoglycemia was associated with increased risk of low executive function (RD, 0.05; 95{\%} CI, 0.01 to 0.10 and RR, 2.32; 95{\%} CI, 1.17 to 4.59) and visual motor function (RD, 0.03; 95{\%} CI, 0.01 to 0.06 and RR, 3.67; 95{\%} CI, 1.15 to 11.69), with highest risk in children exposed to severe, recurrent, or clinically undetected (interstitial episodes only) hypoglycemia. CONCLUSIONS AND RELEVANCE: Neonatal hypoglycemia was not associated with increased risk of combined neurosensory impairment at 4.5 years but was associated with a dose-dependent increased risk of poor executive function and visual motor function, even if not detected clinically, and may thus influence later learning. Randomized trials are needed to determine optimal screening and intervention thresholds based on assessment of neurodevelopment at least to school age.",
keywords = "Blood Glucose, Child Development, Child, Preschool, Cohort Studies, Female, Humans, Hypoglycemia/complications, Infant, Infant, Newborn, Infant, Newborn, Diseases, Male, Neurodevelopmental Disorders/epidemiology, New Zealand/epidemiology, Prospective Studies",
author = "{Children With Hypoglycemia and Their Later Development (CHYLD) Study Team} and McKinlay, {Christopher J.D.} and Alsweiler, {Jane M.} and Anstice, {Nicola S.} and Nataliia Burakevych and Arijit Chakraborty and Chase, {J. Geoffrey} and Gamble, {Gregory D.} and Harris, {Deborah L.} and Jacobs, {Robert J.} and Yannan Jiang and Nabin Paudel and {San Diego}, {Ryan J.} and Benjamin Thompson and Wouldes, {Trecia A.} and Harding, {Jane E.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1001/jamapediatrics.2017.1579",
language = "English",
volume = "171",
pages = "972--983",
journal = "Archives of Pediatrics and Adolescent Medicine",
issn = "1072-4710",
publisher = "American Medical Association",
number = "10",

}

Children With Hypoglycemia and Their Later Development (CHYLD) Study Team 2017, 'Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years', JAMA Pediatrics, vol. 171, no. 10, pp. 972-983. https://doi.org/10.1001/jamapediatrics.2017.1579

Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years. / Children With Hypoglycemia and Their Later Development (CHYLD) Study Team.

In: JAMA Pediatrics, Vol. 171, No. 10, 01.10.2017, p. 972-983.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years

AU - Children With Hypoglycemia and Their Later Development (CHYLD) Study Team

AU - McKinlay, Christopher J.D.

AU - Alsweiler, Jane M.

AU - Anstice, Nicola S.

AU - Burakevych, Nataliia

AU - Chakraborty, Arijit

AU - Chase, J. Geoffrey

AU - Gamble, Gregory D.

AU - Harris, Deborah L.

AU - Jacobs, Robert J.

AU - Jiang, Yannan

AU - Paudel, Nabin

AU - San Diego, Ryan J.

AU - Thompson, Benjamin

AU - Wouldes, Trecia A.

AU - Harding, Jane E.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - IMPORTANCE: Hypoglycemia is common during neonatal transition and may cause permanent neurological impairment, but optimal intervention thresholds are unknown. OBJECTIVE: To test the hypothesis that neurodevelopment at 4.5 years is related to the severity and frequency of neonatal hypoglycemia. DESIGN, SETTING, AND PARTICIPANTS: The Children With Hypoglycemia and Their Later Development (CHYLD) Study is a prospective cohort investigation of moderate to late preterm and term infants born at risk of hypoglycemia. Clinicians were masked to neonatal interstitial glucose concentrations; outcome assessors were masked to neonatal glycemic status. The setting was a regional perinatal center in Hamilton, New Zealand. The study was conducted from December 2006 to November 2010. The dates of the follow-up were September 2011 to June 2015. Participants were 614 neonates born from 32 weeks’ gestation with at least 1 risk factor for hypoglycemia, including diabetic mother, preterm, small, large, or acute illness. Blood and masked interstitial glucose concentrations were measured for up to 7 days after birth. Infants with hypoglycemia (whole-blood glucose concentration <47 mg/dL) were treated to maintain blood glucose concentration of at least 47 mg/dL. EXPOSURES: Neonatal hypoglycemic episode, defined as at least 1 consecutive blood glucose concentration less than 47 mg/dL, a severe episode (<36 mg/dL), or recurrent (3 episodes). An interstitial episode was defined as an interstitial glucose concentration less than 47 mg/dL for at least 10 minutes. MAIN OUTCOMES AND MEASURES: Cognitive function, executive function, visual function, and motor function were assessed at 4.5 years. The primary outcome was neurosensory impairment, defined as poor performance in one or more domains. RESULTS: In total, 477 of 604 eligible children (79.0%) were assessed. Their mean (SD) age at the time of assessment was 4.5 (0.1) years, and 228 (47.8%) were female. Those exposed to neonatal hypoglycemia (280 [58.7%]) did not have increased risk of neurosensory impairment (risk difference [RD], 0.01; 95% CI, −0.07 to 0.10 and risk ratio [RR], 0.96; 95% CI, 0.77 to 1.21). However, hypoglycemia was associated with increased risk of low executive function (RD, 0.05; 95% CI, 0.01 to 0.10 and RR, 2.32; 95% CI, 1.17 to 4.59) and visual motor function (RD, 0.03; 95% CI, 0.01 to 0.06 and RR, 3.67; 95% CI, 1.15 to 11.69), with highest risk in children exposed to severe, recurrent, or clinically undetected (interstitial episodes only) hypoglycemia. CONCLUSIONS AND RELEVANCE: Neonatal hypoglycemia was not associated with increased risk of combined neurosensory impairment at 4.5 years but was associated with a dose-dependent increased risk of poor executive function and visual motor function, even if not detected clinically, and may thus influence later learning. Randomized trials are needed to determine optimal screening and intervention thresholds based on assessment of neurodevelopment at least to school age.

AB - IMPORTANCE: Hypoglycemia is common during neonatal transition and may cause permanent neurological impairment, but optimal intervention thresholds are unknown. OBJECTIVE: To test the hypothesis that neurodevelopment at 4.5 years is related to the severity and frequency of neonatal hypoglycemia. DESIGN, SETTING, AND PARTICIPANTS: The Children With Hypoglycemia and Their Later Development (CHYLD) Study is a prospective cohort investigation of moderate to late preterm and term infants born at risk of hypoglycemia. Clinicians were masked to neonatal interstitial glucose concentrations; outcome assessors were masked to neonatal glycemic status. The setting was a regional perinatal center in Hamilton, New Zealand. The study was conducted from December 2006 to November 2010. The dates of the follow-up were September 2011 to June 2015. Participants were 614 neonates born from 32 weeks’ gestation with at least 1 risk factor for hypoglycemia, including diabetic mother, preterm, small, large, or acute illness. Blood and masked interstitial glucose concentrations were measured for up to 7 days after birth. Infants with hypoglycemia (whole-blood glucose concentration <47 mg/dL) were treated to maintain blood glucose concentration of at least 47 mg/dL. EXPOSURES: Neonatal hypoglycemic episode, defined as at least 1 consecutive blood glucose concentration less than 47 mg/dL, a severe episode (<36 mg/dL), or recurrent (3 episodes). An interstitial episode was defined as an interstitial glucose concentration less than 47 mg/dL for at least 10 minutes. MAIN OUTCOMES AND MEASURES: Cognitive function, executive function, visual function, and motor function were assessed at 4.5 years. The primary outcome was neurosensory impairment, defined as poor performance in one or more domains. RESULTS: In total, 477 of 604 eligible children (79.0%) were assessed. Their mean (SD) age at the time of assessment was 4.5 (0.1) years, and 228 (47.8%) were female. Those exposed to neonatal hypoglycemia (280 [58.7%]) did not have increased risk of neurosensory impairment (risk difference [RD], 0.01; 95% CI, −0.07 to 0.10 and risk ratio [RR], 0.96; 95% CI, 0.77 to 1.21). However, hypoglycemia was associated with increased risk of low executive function (RD, 0.05; 95% CI, 0.01 to 0.10 and RR, 2.32; 95% CI, 1.17 to 4.59) and visual motor function (RD, 0.03; 95% CI, 0.01 to 0.06 and RR, 3.67; 95% CI, 1.15 to 11.69), with highest risk in children exposed to severe, recurrent, or clinically undetected (interstitial episodes only) hypoglycemia. CONCLUSIONS AND RELEVANCE: Neonatal hypoglycemia was not associated with increased risk of combined neurosensory impairment at 4.5 years but was associated with a dose-dependent increased risk of poor executive function and visual motor function, even if not detected clinically, and may thus influence later learning. Randomized trials are needed to determine optimal screening and intervention thresholds based on assessment of neurodevelopment at least to school age.

KW - Blood Glucose

KW - Child Development

KW - Child, Preschool

KW - Cohort Studies

KW - Female

KW - Humans

KW - Hypoglycemia/complications

KW - Infant

KW - Infant, Newborn

KW - Infant, Newborn, Diseases

KW - Male

KW - Neurodevelopmental Disorders/epidemiology

KW - New Zealand/epidemiology

KW - Prospective Studies

UR - http://www.scopus.com/inward/record.url?scp=85030774989&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/association-neonatal-glycemia-neurodevelopmental-outcomes-45-years-2

U2 - 10.1001/jamapediatrics.2017.1579

DO - 10.1001/jamapediatrics.2017.1579

M3 - Article

VL - 171

SP - 972

EP - 983

JO - Archives of Pediatrics and Adolescent Medicine

JF - Archives of Pediatrics and Adolescent Medicine

SN - 1072-4710

IS - 10

ER -

Children With Hypoglycemia and Their Later Development (CHYLD) Study Team. Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years. JAMA Pediatrics. 2017 Oct 1;171(10):972-983. https://doi.org/10.1001/jamapediatrics.2017.1579